Federation des caisses Desjardins du Quebec Decreases Holdings in Abbott Laboratories $ABT

Key Points

• The Federation des caisses Desjardins du Quebec reduced its holdings in Abbott Laboratories by 12.4%, selling 28,294 shares and now owning 200,788 shares valued at approximately $26.6 million.
• In the 1st quarter, other institutional investors also adjusted their positions, with EP Wealth Advisors increasing their holdings by 13.9% and GW Henssler & Associates raising theirs by 34.8%.
• Abbott Laboratories recently reported a quarterly earnings per share (EPS) of $1.26, meeting analysts' expectations, with a revenue of $11.14 billion, up 7.4% year-over-year.

Federation des caisses Desjardins du Quebec reduced its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 12.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 200,788 shares of the healthcare product maker's stock after selling 28,294 shares during the quarter. Federation des caisses Desjardins du Quebec's holdings in Abbott Laboratories were worth $26,641,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in ABT. Hughes Financial Services LLC purchased a new stake in Abbott Laboratories during the 1st quarter valued at $27,000. Abound Financial LLC purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $28,000. Elequin Capital LP purchased a new stake in Abbott Laboratories in the 1st quarter worth about $30,000. Wormser Freres Gestion purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $32,000. Finally, JCIC Asset Management Inc. purchased a new position in shares of Abbott Laboratories during the first quarter worth approximately $32,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.46% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ABT has been the subject of several research reports. Raymond James Financial lowered their price objective on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research note on Friday, July 18th. Leerink Partners assumed coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a "market perform" rating and a $143.00 price objective for the company. Evercore ISI boosted their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Morgan Stanley increased their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Finally, Leerink Partnrs upgraded shares of Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $144.47.

Abbott Laboratories Trading Up 0.1%

NYSE:ABT traded up $0.11 on Friday, hitting $132.92. 3,286,796 shares of the stock were exchanged, compared to its average volume of 5,085,004. The stock has a market capitalization of $231.33 billion, a price-to-earnings ratio of 16.66, a P/E/G ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The company's 50-day moving average price is $130.68 and its 200 day moving average price is $131.39.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same period in the previous year, the firm earned $1.14 EPS. Abbott Laboratories's quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date was Tuesday, July 15th. Abbott Laboratories's payout ratio is currently 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.